Company intelligence / Profile preview

Henan Maiyingnuo Pharmaceutical Technology

Zhengzhou, Henan, Chinapharmaceutical-technology.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Henan Maiyingnuo Pharmaceutical Technology develops small molecule therapeutics with its lead candidate, MDI–1228, currently in Phase I clinical trials targeting allergic conjunctivitis and atopic dermatitis. The drug is administered as a topical or ophthalmic gel. No published clinical results are available yet; the program remains early-stage with a high phase transition success rate benchmarked for this indication class.

Therapeutic areas: OtherDermatologyImmunology
Modalities: Small molecules (topical and ophthalmic gel)
Industry: Biotech

Drug pipeline

1 asset

MDI-1228

Phase 1

Indications: Allergic conjunctivitis, Atopic dermatitis

Beyond the preview

Go deeper on Henan Maiyingnuo Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Henan Maiyingnuo Pharmaceutical Technology.

Explore the full profile